AU2015314756A1 - Combination therapies of alk inhibitors - Google Patents

Combination therapies of alk inhibitors Download PDF

Info

Publication number
AU2015314756A1
AU2015314756A1 AU2015314756A AU2015314756A AU2015314756A1 AU 2015314756 A1 AU2015314756 A1 AU 2015314756A1 AU 2015314756 A AU2015314756 A AU 2015314756A AU 2015314756 A AU2015314756 A AU 2015314756A AU 2015314756 A1 AU2015314756 A1 AU 2015314756A1
Authority
AU
Australia
Prior art keywords
cancer
inhibitor
antibody
combination
ldk378
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015314756A
Other languages
English (en)
Inventor
Yi Yang Lau
David Lebwohl
Nanxin LI
Malte Peters
Jeffrey Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2015314756A1 publication Critical patent/AU2015314756A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: LAU, Yvonne, NOVARTIS AG, SCOTT, JEFFREY
Priority to AU2018250507A priority Critical patent/AU2018250507B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2015314756A 2014-09-13 2015-09-11 Combination therapies of alk inhibitors Abandoned AU2015314756A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018250507A AU2018250507B2 (en) 2014-09-13 2018-10-19 Combination therapies of alk inhibitors

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462050116P 2014-09-13 2014-09-13
US62/050,116 2014-09-13
US201462059788P 2014-10-03 2014-10-03
US62/059,788 2014-10-03
US201562119060P 2015-02-20 2015-02-20
US62/119,060 2015-02-20
US201562199030P 2015-07-30 2015-07-30
US62/199,030 2015-07-30
PCT/US2015/049810 WO2016040880A1 (en) 2014-09-13 2015-09-11 Combination therapies of alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018250507A Division AU2018250507B2 (en) 2014-09-13 2018-10-19 Combination therapies of alk inhibitors

Publications (1)

Publication Number Publication Date
AU2015314756A1 true AU2015314756A1 (en) 2017-03-16

Family

ID=54186328

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015314756A Abandoned AU2015314756A1 (en) 2014-09-13 2015-09-11 Combination therapies of alk inhibitors
AU2018250507A Expired - Fee Related AU2018250507B2 (en) 2014-09-13 2018-10-19 Combination therapies of alk inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018250507A Expired - Fee Related AU2018250507B2 (en) 2014-09-13 2018-10-19 Combination therapies of alk inhibitors

Country Status (12)

Country Link
US (4) US11344620B2 (enExample)
EP (5) EP3191097B1 (enExample)
JP (1) JP6681905B2 (enExample)
KR (1) KR20170060042A (enExample)
CN (1) CN107206071A (enExample)
AU (2) AU2015314756A1 (enExample)
BR (1) BR112017004826A2 (enExample)
CA (1) CA2960824A1 (enExample)
ES (1) ES2771926T3 (enExample)
MX (1) MX2017003227A (enExample)
RU (1) RU2718914C2 (enExample)
WO (3) WO2016040892A1 (enExample)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2842462C (en) * 2011-07-20 2020-01-28 Brigham Young University Hydrogel materials incorporating eluting ceragenin compound
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
KR20170060042A (ko) * 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
EA201790737A1 (ru) * 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
KR20170101925A (ko) * 2014-12-02 2017-09-06 셀진 코포레이션 병용 요법
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
DE112016002056T5 (de) 2015-05-06 2018-02-08 Snipr Technologies Limited Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
CA2992298A1 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
US10894044B2 (en) 2015-09-16 2021-01-19 Board Of Regents, The University Of Texas System Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
IL292080B2 (en) 2015-11-11 2024-09-01 Celator Pharmaceuticals Inc Treatment regimens for hematologic cancers and methods of use thereof
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
SG11201808306PA (en) 2016-03-24 2018-10-30 Tragara Pharmaceuticals Inc Treatment of cancer with tg02
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
RU2754452C2 (ru) 2016-04-12 2021-09-02 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR102463617B1 (ko) * 2016-05-20 2022-11-03 일라이 릴리 앤드 캄파니 Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법
JP2019516767A (ja) 2016-05-23 2019-06-20 イーライ リリー アンド カンパニー 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ
WO2017202962A1 (en) * 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
MA45123A (fr) 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
GB201609811D0 (en) * 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
US20190269666A1 (en) * 2016-07-29 2019-09-05 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US20190247399A1 (en) * 2016-09-09 2019-08-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
EP3522923A1 (en) 2016-10-06 2019-08-14 Pfizer Inc Dosing regimen of avelumab for the treatment of cancer
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
AU2017359333B2 (en) * 2016-11-08 2024-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
US11230596B2 (en) 2016-11-30 2022-01-25 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
WO2018106729A1 (en) 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
MX2019010086A (es) * 2017-02-27 2020-02-12 Novartis Ag Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.
CN110621337B (zh) * 2017-05-10 2021-11-09 浙江时迈药业有限公司 抗lag3人单克隆抗体及其用途
EP3655531B1 (en) * 2017-07-18 2024-09-04 Exosome Diagnostics, Inc. Sequencing of nucleic acids associated with exosomal isolation from patients with glioblastoma multiforme
EP3675877A1 (en) 2017-08-31 2020-07-08 Multimmune GmbH Hsp70 based combination therapy
CN109663130B (zh) * 2017-10-13 2021-06-29 江苏恒瑞医药股份有限公司 Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
EA202090746A1 (ru) 2017-11-03 2020-08-17 Ориджен Дискавери Текнолоджис Лимитед Двойные ингибиторы путей tim-3 и pd-1
CN111386128A (zh) 2017-11-06 2020-07-07 奥瑞基尼探索技术有限公司 用于免疫调节的联合疗法
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
CA3082095A1 (en) * 2017-11-10 2019-05-16 Elevar Therapeutics, Inc. A combination therapy with apatinib for the treatment of cancer
CN109806393B (zh) * 2017-11-17 2022-07-26 江苏恒瑞医药股份有限公司 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
TWI762743B (zh) 2017-11-29 2022-05-01 日商大鵬藥品工業股份有限公司 磺醯胺化合物及其用途
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
US20210379024A1 (en) 2018-03-14 2021-12-09 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
JP7520366B2 (ja) * 2018-04-16 2024-07-23 オンクオリティー ファーマシューティカルズ チャイナ リミテッド 腫瘍療法の副作用の予防または治療方法
CN112996502B (zh) * 2018-05-16 2023-10-31 普罗维克图斯药品技术公司 卤代呫吨针对难治性小儿实体瘤的体外和异种移植抗肿瘤活性
CN112423845B (zh) 2018-07-12 2024-07-30 F-星治疗有限公司 结合pd-l1和cd137的抗体分子
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
CA3106048A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20210073490A (ko) * 2018-08-08 2021-06-18 어센테지 파마 (쑤저우) 컴퍼니 리미티드 면역요법과 mdm2 억제제의 병용
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
BR112021007283A2 (pt) 2018-10-19 2021-07-20 Senhwa Biosciences, Inc. método de tratamento de um câncer ou câncer refratário
US20210379046A1 (en) * 2018-11-01 2021-12-09 Memorial Sloan Kettering Cancer Center Methods of Treating Diseases Using Kinase Modulators
EP3897607A4 (en) * 2018-12-20 2022-08-24 Rafael Pharmaceuticals, Inc. COMPOSITIONS AND METHODS OF THERAPY FOR TREATING CANCER USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACID AND AN AUTOPHAGY INHIBITOR
WO2020172233A1 (en) * 2019-02-22 2020-08-27 The Trustees Of Columbia University In The City Of New York Treatment of prostate cancer by androgen ablation and il-8 blockade
JP2022524629A (ja) * 2019-03-15 2022-05-09 重▲慶▼医葯工▲業▼研究院有限責任公司 抗腫瘍薬の調製におけるキノリン誘導体と免疫調節剤の組み合わせの使用
EP3962559B1 (en) * 2019-04-26 2025-04-16 University of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CA3141531A1 (en) * 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
WO2020264160A1 (en) 2019-06-28 2020-12-30 Donald Picker Preparation of preliposomal annamycin lyophilizate
EP3990041B1 (en) 2019-06-28 2025-08-06 Board of Regents, The University of Texas System Method of reconstituting liposomal annamycin
CN110407938B (zh) * 2019-08-12 2020-03-06 北京昭衍生物技术有限公司 抗tim-3单克隆抗体、表达载体及其应用
CN110687282B (zh) * 2019-08-26 2023-05-23 中国医学科学院肿瘤医院 PD-1和/或p53自身抗体作为肿瘤疗效预测或预后评估的标志物
CA3154079A1 (en) * 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
GB201915618D0 (en) * 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
KR20220092578A (ko) * 2019-11-05 2022-07-01 브리스톨-마이어스 스큅 컴퍼니 M-단백질 검정 및 이의 용도
CN114728942A (zh) * 2019-11-21 2022-07-08 德州大学系统董事会 用脂质体安那霉素的靶向肺的抗癌疗法
US20230092707A1 (en) * 2020-03-05 2023-03-23 Merck Sharp & Dohme Llc Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody
US20230102924A1 (en) * 2020-03-10 2023-03-30 Emory University Methods of Treating Cancer Using Checkpoint Inhibitors in Combination with Purine Cleaving Enzymes
EP4139352A1 (en) * 2020-04-22 2023-03-01 Chemomab Ltd. Method of treatment using anti-ccl24 antibody
US20230181593A1 (en) * 2020-05-21 2023-06-15 The Regents Of The University Of California Compositions and methods for treating breast cancer
WO2021244551A1 (zh) * 2020-06-02 2021-12-09 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
TW202216768A (zh) 2020-06-22 2022-05-01 美商恩格姆生物製藥公司 Ｌａｉｒ－１結合劑及其使用方法
CN116261455B (zh) * 2020-09-25 2024-11-01 苏州亚盛药业有限公司 一种药物组合物及其在治疗癌症中的用途
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022170060A1 (en) * 2021-02-05 2022-08-11 Verastem, Inc. Combination therapy for treating abnormal cell growth
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116370476B (zh) * 2023-04-21 2024-01-30 遵义医科大学 一种化疗药物组合物及其应用
WO2025171187A1 (en) * 2024-02-06 2025-08-14 Genprex, Inc. Treatment of alk positive cancers

Family Cites Families (369)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU1807188A (en) 1987-04-10 1988-11-04 Xoma Corporation Human monoclonal antibodies binding determinants of gram negative bacteria
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JPH06506105A (ja) 1990-08-29 1994-07-14 ファーミング　ビーブイ 哺乳動物細胞における相同性組換え
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0606217T4 (da) 1991-06-27 2009-03-30 Bristol Myers Squibb Co CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CA2230759C (en) 1995-08-29 2012-02-21 Kirin Beer Kabushiki Kaisha Chimeric animal and method for producing the same
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
WO1999052552A1 (en) 1998-04-15 1999-10-21 Brigham & Women's Hospital, Inc. T cell inhibitory receptor compositions and uses thereof
AU774962B2 (en) 1998-12-03 2004-07-15 Regents Of The University Of California, The Stimulation of T cells against self antigens using CTLA-4 blocking agents
CA2346448A1 (en) 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
FR2794025A1 (fr) 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
AU6085700A (en) 1999-07-12 2001-01-30 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
JP2004501624A (ja) 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2001291087A1 (en) 2000-09-20 2002-04-02 Amgen Inc. B7-like molecules and uses thereof
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
IL155514A0 (en) 2000-10-20 2003-11-23 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
KR20030066657A (ko) 2000-11-15 2003-08-09 오노 야꾸힝 고교 가부시키가이샤 Ｐｄ-1 결손 마우스 및 그 용도
JP2002194491A (ja) 2000-12-27 2002-07-10 Daido Steel Co Ltd ばね用鋼材
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
US6727072B2 (en) 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US6592849B2 (en) 2001-06-21 2003-07-15 Colgate Palmolive Company Chewing gum to control malodorous breath
EP1406653A4 (en) 2001-06-29 2005-05-04 Univ Leland Stanford Junior T CELL REGULATION GENES AND METHOD OF USE THEREOF
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
JP2003029846A (ja) 2001-07-11 2003-01-31 Sanyo Electric Co Ltd 流量調整器および流量調整器を備えた飲料供給装置
US20040241745A1 (en) 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
ES2555307T3 (es) 2002-03-08 2015-12-30 Eisai R&D Management Co., Ltd. Compuestos macrocíclicos útiles como agentes farmacéuticos
CA2478374C (en) 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
US7449300B2 (en) 2002-11-21 2008-11-11 Mayo Foundation For Medical Education And Research Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
JP2006523226A (ja) 2003-02-28 2006-10-12 ザ ジョンズ ホプキンス ユニバーシティ Ｔ細胞調節方法
NZ543654A (en) 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
BRPI0414924A (pt) 2003-10-03 2006-11-07 Brigham & Womens Hospital ligantes de tim-3 e seus métodos
DK1684805T3 (da) * 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
EA200601761A1 (ru) 2004-03-24 2007-06-29 Телос Фармасьютикалз, Инк. Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
PT1761528E (pt) 2004-06-11 2008-04-15 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JP5902367B2 (ja) 2004-06-30 2016-04-13 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 抗体
WO2006021955A2 (en) 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
KR20160058972A (ko) 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
PT3428191T (pt) 2004-10-06 2024-12-30 Mayo Found Medical Education & Res B7-h1 e tratamento do carcinona de células renais
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
WO2007004415A1 (ja) 2005-07-01 2007-01-11 Murata Manufacturing Co., Ltd. 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
AU2006272837B2 (en) 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
US20090215084A1 (en) 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PE20110224A1 (es) 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
WO2008024725A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
RS53588B1 (sr) 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
BRPI0720264B1 (pt) 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
NZ720288A (en) 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2514762B1 (en) 2007-07-13 2015-04-08 The Johns Hopkins University B7-DC variants
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
EP2195347A1 (en) 2007-08-17 2010-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
WO2009030285A1 (en) 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
TWI471134B (zh) 2007-09-12 2015-02-01 Genentech Inc 肌醇磷脂３－激酶抑制劑化合物及化療劑之組合及使用方法
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
PL2222675T3 (pl) 2007-12-19 2014-02-28 Genentech Inc 5-anilinoimidazopirydyny i sposoby zastosowania
PT4160212T (pt) 2008-01-15 2024-06-25 Univ Leland Stanford Junior Marcadores de células estaminais de leucemia mielóide aguda
US20110059106A1 (en) 2008-01-29 2011-03-10 Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
ES2554513T3 (es) 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
EP2307050A4 (en) 2008-07-04 2012-07-25 Ono Pharmaceutical Co USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
WO2010056735A1 (en) 2008-11-11 2010-05-20 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
CN102282265B (zh) 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
SG171812A1 (en) 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010084999A1 (en) 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
WO2010102278A1 (en) 2009-03-06 2010-09-10 President And Fellows Of Harvard College Methods and compositions for the generation and maintenance of regulatory t cells
WO2010110346A1 (ja) 2009-03-24 2010-09-30 独立行政法人理化学研究所 白血病幹細胞マーカー
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
LT2990421T (lt) 2009-04-30 2018-04-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti-ceacam1 antikūnai ir jų panaudojimo būdai
AU2010242830C1 (en) 2009-05-01 2014-02-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012525441A (ja) 2009-05-01 2012-10-22 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびこの使用
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
DK2769737T3 (en) 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
TW201119673A (en) 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
CA2775761C (en) 2009-09-30 2018-08-28 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
UY32948A (es) 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
WO2011100841A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
DK2560683T4 (da) 2010-04-23 2022-08-29 Hoffmann La Roche Fremstilling af heteromultimeriske proteiner
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
EP2571532B1 (en) 2010-05-14 2017-05-03 Abbvie Inc. Il-1 binding proteins
HUE040213T2 (hu) 2010-06-11 2019-02-28 Kyowa Hakko Kirin Co Ltd Anti-TIM antitest
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012018538A2 (en) 2010-07-26 2012-02-09 Schering Corporation Bioassays for determining pd-1 modulation
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
MX2013004979A (es) 2010-11-02 2013-07-30 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR083705A1 (es) 2010-11-04 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130330350A1 (en) 2010-11-09 2013-12-12 Medimmune, Llc Antibody Scaffold For Homogenous Conjugation
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US8814630B2 (en) 2011-01-04 2014-08-26 Carl T. Rittberger PVC beehive
JP6161540B2 (ja) 2011-02-04 2017-07-12 ジェネンテック， インコーポレイテッド Ｆｃ変異体及びそれらの生産方法
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
EP2723381A4 (en) 2011-06-21 2015-03-18 Univ Johns Hopkins FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
JP2014527983A (ja) 2011-09-19 2014-10-23 ザ ジョンズ ホプキンス ユニバーシティー 癌免疫療法
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013059740A1 (en) * 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
IN2014CN03072A (enExample) 2011-10-31 2015-07-31 Merck Sharp & Dohme
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
EP2785743B1 (en) 2011-12-01 2019-08-14 The Brigham and Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
CN102492038B (zh) 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
JP6445426B2 (ja) * 2012-05-10 2018-12-26 ザ ジェネラル ホスピタル コーポレイション ヌクレオチド配列を決定する方法
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2013179174A1 (en) 2012-05-29 2013-12-05 Koninklijke Philips N.V. Lighting arrangement
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
JO3300B1 (ar) * 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
KR101566538B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
AU2013295855A1 (en) 2012-07-27 2015-02-12 Novartis Ag Prediction of treatment response to JAK/STAT inhibitor
EP2879498A4 (en) 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
AU2013327116C1 (en) * 2012-10-02 2018-08-30 Bristol-Myers Squibb Company Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
JP6461800B2 (ja) 2012-10-04 2019-01-30 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
CN104853776B (zh) 2012-10-12 2021-04-09 布里格姆及妇女医院股份有限公司 免疫应答的增强
KR102156398B1 (ko) * 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
UA115151C2 (uk) 2012-11-08 2017-09-25 Новартіс Аг Фармацевтична комбінація, що містить інгібітор b-raf та інгібітор деацетилази гістонів, та її застосування при лікуванні проліферативних захворювань
HK1211475A1 (en) 2012-11-28 2016-05-27 Novartis Ag Combination therapy
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
CN103242448B (zh) 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
KR20160013049A (ko) 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
DK3021869T3 (da) 2013-07-16 2020-09-21 Hoffmann La Roche Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
KR102232153B1 (ko) 2013-08-20 2021-03-24 머크 샤프 앤드 돔 코포레이션 Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015036394A1 (en) 2013-09-10 2015-03-19 Medimmune Limited Antibodies against pd-1 and uses thereof
RU2701327C2 (ru) 2013-09-11 2019-09-25 Медиммьюн Лимитед Антитела к b7-h1 для лечения опухолей
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
RS59880B1 (sr) 2013-09-27 2020-03-31 Hoffmann La Roche Formulacije za anti-pdl1 antitelo
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
US20150125386A1 (en) 2013-11-05 2015-05-07 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
EP3074035B1 (en) 2013-11-25 2020-05-13 FameWave Ltd. Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
US20160303231A1 (en) 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP4070818A3 (en) 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CN105263521B (zh) 2014-01-15 2021-06-29 卡德门企业有限公司 免疫调节剂
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2938566A1 (en) 2014-02-04 2015-08-13 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CN105979961B (zh) 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
SG11201606577YA (en) 2014-02-10 2016-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
EP3114144A1 (en) 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
US20170158776A1 (en) 2014-05-15 2017-06-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US9885721B2 (en) 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
EA201790737A1 (ru) * 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
WO2016079049A1 (en) 2014-11-17 2016-05-26 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
SG10201909173PA (en) 2015-04-01 2019-11-28 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
NZ735820A (en) 2015-04-17 2025-02-28 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
BR112018001640A2 (pt) 2015-07-29 2018-09-18 Novartis Ag combinação de antagonista da pd-1 com um inibidor de egfr
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
JP6840127B2 (ja) 2015-07-29 2021-03-10 ノバルティス アーゲー がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
SG10202111808WA (en) 2015-08-11 2021-11-29 Novartis Ag 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
PL3386541T3 (pl) 2015-12-07 2021-04-06 Merck Patent Gmbh Wodna formulacja farmaceutyczna zawierającą przeciwciało anty-pd-1 awelumab
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
JP2019514889A (ja) 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
US11406633B2 (en) 2017-02-14 2022-08-09 Novartis Ag Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
KR20250025039A (ko) 2017-07-20 2025-02-20 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
WO2019018640A1 (en) 2017-07-21 2019-01-24 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
BR112020018755A2 (pt) 2018-03-20 2021-01-05 Novartis Ag Combinações farmacêuticas
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN114786680A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 Tim-3抑制剂及其用途
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia

Also Published As

Publication number Publication date
US20170296659A1 (en) 2017-10-19
AU2018250507B2 (en) 2020-02-06
MX2017003227A (es) 2017-12-04
BR112017004826A2 (pt) 2017-12-12
EP3659621A1 (en) 2020-06-03
WO2016040892A1 (en) 2016-03-17
WO2016040882A1 (en) 2016-03-17
US20170281624A1 (en) 2017-10-05
AU2018250507A1 (en) 2018-11-15
CN107206071A (zh) 2017-09-26
JP6681905B2 (ja) 2020-04-15
EP3191127A1 (en) 2017-07-19
EP3191126A1 (en) 2017-07-19
CA2960824A1 (en) 2016-03-17
ES2771926T3 (es) 2020-07-07
EP3191126B1 (en) 2020-05-13
US9993551B2 (en) 2018-06-12
RU2718914C2 (ru) 2020-04-15
US20240075136A1 (en) 2024-03-07
EP3925622A1 (en) 2021-12-22
EP3191097A1 (en) 2017-07-19
US20170304443A1 (en) 2017-10-26
US11344620B2 (en) 2022-05-31
EP3191097B1 (en) 2019-10-23
RU2017112379A3 (enExample) 2019-04-17
KR20170060042A (ko) 2017-05-31
JP2017532372A (ja) 2017-11-02
WO2016040880A1 (en) 2016-03-17
RU2017112379A (ru) 2018-10-15

Similar Documents

Publication Publication Date Title
US20240075136A1 (en) Combination therapies
EP3200775B1 (en) Combination therapies
CA2936962C (en) Antibody molecules to lag-3 and uses thereof
AU2015209145A1 (en) Antibody molecules to PD-1 and uses thereof
HK40019395A (en) Combination therapies
HK1242582B (en) Combination therapies
HK1242582A1 (en) Combination therapies
HK40031258A (en) Antibody molecules to lag-3 and uses thereof
HK1229355B (en) Antibody molecules to lag-3 and uses thereof
HK1229355A1 (en) Antibody molecules to lag-3 and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LEBWOHL, DAVID; PETERS MALTE; LI, NANXIN; LAU, YI YANG AND SCOTT, JEFFREY

PC1 Assignment before grant (sect. 113)

Owner name: NOVARTIS AG

Free format text: FORMER APPLICANT(S): LAU, YVONNE; SCOTT, JEFFREY; NOVARTIS AG

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted